These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 24803998

  • 1. Longitudinal Study on Liver Functions in Patients with Thalassemia Major before and after Deferasirox (DFX) Therapy.
    Soliman A, Yassin M, Al Yafei F, Al-Naimi L, Almarri N, Sabt A, De Sanctis V.
    Mediterr J Hematol Infect Dis; 2014; 6(1):e2014025. PubMed ID: 24803998
    [Abstract] [Full Text] [Related]

  • 2. Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles.
    Yassin MA, Soliman AT, De Sanctis V, Hussein RM, Al-Okka R, Kassem N, Ghasoub R, Basha A, Nashwan AJ, Adel AM.
    Mediterr J Hematol Infect Dis; 2018; 10(1):e2018064. PubMed ID: 30416696
    [Abstract] [Full Text] [Related]

  • 3. Statural Growth and Prevalence of Endocrinopathies in Relation to Liver Iron Content (LIC) in Adult Patients with Beta Thalassemia Major (BTM) and Sickle Cell Disease (SCD).
    Yassin MA, Soliman AT, De Sanctis V, Abdula MAJ, Riaz LM, Ghori FF, Yousaf A, Nashwan AJ, Abusamaan S, Moustafa A, Kohla S, Soliman DS.
    Acta Biomed; 2018 Feb 16; 89(2-S):33-40. PubMed ID: 29451227
    [Abstract] [Full Text] [Related]

  • 4. Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.
    Soliman AT, Yassin MA, De Sanctis V.
    Acta Biomed; 2018 Feb 16; 89(2-S):27-32. PubMed ID: 29451226
    [Abstract] [Full Text] [Related]

  • 5. Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.
    Hassan MA, Tolba OA.
    Electron Physician; 2016 May 16; 8(5):2425-31. PubMed ID: 27382454
    [Abstract] [Full Text] [Related]

  • 6. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
    Aydinok Y, Unal S, Oymak Y, Vergin C, Türker ZD, Yildiz D, Yesilipek A.
    Eur J Haematol; 2012 May 16; 88(5):431-8. PubMed ID: 22335829
    [Abstract] [Full Text] [Related]

  • 7. Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy.
    Senol SP, Tiftik EN, Unal S, Akdeniz A, Tasdelen B, Tunctan B.
    J Basic Clin Pharm; 2016 Mar 16; 7(2):49-59. PubMed ID: 27057126
    [Abstract] [Full Text] [Related]

  • 8. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May 16; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 9. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 16; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 10. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep 16; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr 16; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
    Dou H, Qin Y, Chen G, Zhao Y.
    Acta Haematol; 2019 Apr 16; 141(1):32-42. PubMed ID: 30504715
    [Abstract] [Full Text] [Related]

  • 13. Severe Liver Iron Concentrations (LIC) in 24 Patients with β-Thalassemia Major: Correlations with Serum Ferritin, Liver Enzymes and Endocrine Complications.
    Kanbour I, Chandra P, Soliman A, De Sanctis V, Nashwan A, Abusamaan S, Moustafa A, Yassin MA.
    Mediterr J Hematol Infect Dis; 2018 Apr 16; 10(1):e2018062. PubMed ID: 30416694
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M, Arandi N, Haghpanah S, Ansari S, Azarkeyvan A, Bordbar M, Safaei S.
    Hemoglobin; 2015 Apr 16; 39(5):327-9. PubMed ID: 26114738
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and Management of Transfusional Iron Overload in Syrian Beta Thalassemia Major Patients Pre and during the Syrian Conflict.
    Touma H, Youssef LA, Al-Salhi L, Ismail Al-Khalil W, AlKeba K.
    Biomed Res Int; 2023 Apr 16; 2023():8911518. PubMed ID: 37743972
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.
    Jaiswal S, Hishikar R, Khandwal O, Agarwal M, Joshi U, Halwai A, Maheshwari B, Sheohare R.
    J Clin Diagn Res; 2017 Feb 16; 11(2):FC01-FC03. PubMed ID: 28384880
    [Abstract] [Full Text] [Related]

  • 17. Using of deferasirox and deferoxamine in refractory iron overload thalassemia.
    Takpradit C, Viprakasit V, Narkbunnam N, Vathana N, Phuakpet K, Pongtanakul B, Sanpakit K, Buaboonnam J.
    Pediatr Int; 2021 Apr 16; 63(4):404-409. PubMed ID: 32856363
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar 16; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 19. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E, Agapidou A, Spanos G, Klonizakis P, Vetsiou E, Mavroudi M, Boura P.
    Hemoglobin; 2015 Mar 16; 39(5):299-304. PubMed ID: 26177199
    [Abstract] [Full Text] [Related]

  • 20. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan 16; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.